Lycopene inhibition of IGF-induced cancer cell growth depends on the level of cyclin D1

European Journal of Nutrition

Volumn 45, Issue 5, 2006, Pages 275-282

  Nahum, Amit ^a   Zeller, Lior ^a   Danilenko, Michael ^a   Prall, Owen W J ^b   Watts, Colin K W ^b   Sutherland, Robert L ^b   Levy, Joseph ^a   Sharoni, Yoav ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b ST VINCENT S HOSPITAL   (Australia)

Author keywords

Breast cancer; Cell cycle; Cyclin D1; Lycopene; Retinoic acid

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; LYCOPENE; METALLOTHIONEIN; RETINOBLASTOMA PROTEIN; RETINOIC ACID; SOMATOMEDIN; ZINC;

ARTICLE; BREAST CANCER; CANCER GROWTH; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; ENDOMETRIUM CANCER; HUMAN; HUMAN CELL; MITOGENESIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SERUM;

ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; BREAST NEOPLASMS; CAROTENOIDS; CELL CYCLE; CELL DIVISION; CULTURE MEDIA, SERUM-FREE; CYCLIN D1; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; PHOSPHORYLATION; TIME FACTORS; TRETINOIN; TUMOR CELLS, CULTURED;

ATRA; LYCOPERSICON ESCULENTUM;

EID: 33746773068     PISSN: 14366207     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00394-006-0595-x     Document Type: Article

References (33)

1. Jones JI, Clemmons DR (1995) Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 16:3-34
2. Mantzoros CS, Tzonou A, Signorello LB, Stampfer M, Trichopoulos D, Adami HO (1997) Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia. Br J Cancer 76:1115-1118
3. Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, Rosner B, Speizer FE, Pollak M (1998) Circulating concentrations of insulin-like growth factor I and risk of breast cancer. Lancet 351:1393-1396
4. Ma J, Pollak MN, Giovannucci E, Chan JM, Tao Y, Hennekens CH, Stampfer MJ (1999) Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst 91:620-625
5. Yu H, Spitz MR, Mistry J, Gu J, Hong WK, Wu X (1999) Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis. J Natl Cancer Inst 91:151-156
6. Levy J, Bosin E, Feldman B, Giat Y, Miinster A, Danilenko M, Sharoni Y (1995) Lycopene is a more potent inhibitor of human cancer cell proliferation than either α-carotene or β-carotene. Nutr Cancer 24:257-267
7. Amir H, Karas M, Giat J, Danilenko M, Levy R, Yermiahu T, Levy J, Sharoni Y (1999) Lycopene and 1,25-dihydroxyvitamin-D3 cooperate in the inhibition of cell cycle progression and induction of differentiation in HL-60 leukemic cells. Nutr Cancer 33:105-112
8. Karas M, Amir H, Fishman D, Danilenko M, Segal S, Nahum A, Koifinann A, Giat Y, Levy J, Sharoni Y (2000) Lycopene interferes with cell cycle progression and insulin-like growth factor I signaling in mammary cancer cells. Nutr Cancer 36:101-111
9. Nahum A, Hirsch K, Danilenko M, Watts CK, Prall OW, Levy J, Sharoni Y (2001) Lycopene inhibition of cell cycle progression in breast and endometrial cancer cells is associated with reduction in cyclin D levels and retention of p27(Kip l) in the cyclin E-cdk2 complexes. Oncogene 20:3428-3436
10. Sherr CJ (1995) D-type cyclins. Trends Biochem Sci 20:187-190
11. Buckley MF, Sweeney KJ, Hamilton JA, Sini RL, Manning DL, Nicholson RI, deFazio A, Watts CK, Musgrove EA, Sutherland RL (1993) Expression and amplification of cyclin genes in human breast cancer. Oncogene 8:2127-2133
12. Watts CK, Sweeney KJ, Warlters A, Musgrove EA, Sutherland RL (1994) Antiestrogen regulation of cell cycle progression and cyclin D1 gene expression in MCF-7 human breast cancer cells. Breast Cancer Res Treat 31:95-105
13. Carroll JS, Prall OW, Musgrove EA, Sutherland RL (2000) A pure estrogen antagonist inhibits cyclin E-Cdk2 activity in MCF-7 breast cancer cells and induces accumulation of p l30-E2F4 complexes characteristic of quiescence. J Biol Chem 275:38221-38229
14. Planas Silva MD, Weinberg RA (1997) Estrogen-dependent cyclin E-cdk2 activation through p21 redistribution. Mol-Cell-Biol 17:4059-4069
15. Teixeira C, Pratt MAC (1997) CDK2 is a target for retinoic acid-mediated growth inhibition in MCF-7 human breast cancer cells. Mol Endocrinol 11:1191-1202
16. Zhou Q, Stetler Stevenson M, Steeg PS (1997) Inhibition of cyclin D expression in human breast carcinoma cells by retinoids in vitro. Oncogene 15:107-115
17. Musgrove EA, Swarbrick A, Lee CS, Cornish AL, Sutherland RL (1998) Mechanisms of cyclin-dependent kinase inactivation by progestins. Mol Cell Biol 18:1812-1825
18. Wang QM, Jones JB, Studzinski GP (1996) Cyclin-dependent kinase inhibitor p27 as a mediator of the G1-S phase block induced by 1,25-dihydroxyvitamin D3 in HL60 cells. Cancer Res 56:264-267
19. Tabibzadeh S, Kaffka KL, Kilian PL, Satyaswaroop PG (1990) Human endometrial epithelial cell lines for studying steroid and cytokine actions. In Vitro Cell Dev Biol 26:1173-1179
20. Prall OW, Rogan EM, Musgrove EA, Watts CK, Sutherland RL (1998) c-Myc or cyclin D1 mimics estrogen effects on cyclin E-Cdk2 activation and cell cycle reentry. Mol-Cell-Biol 18:4499-4508 issn: 0270-7306
21. Watts CK, Brady A, Sarcevic B, deFazio A, Musgrove EA, Sutherland RL (1995) Antiestrogen inhibition of cell cycle progression in breast cancer cells in associated with inhibition of cyclin-dependent kinase activity and decreased retinoblastoma protein phosphorylation. Mol Endocrinol 9:1804-1813
22. Sherr CJ (1996) Cancer cell cycles. Science 274:1672-1677
23. Ben-Dor A, Steiner M, Gheber L, Danilenko M, Dubi N, Linnewiel K, Zick A, Sharoni Y, Levy J (2005) Carotenoids activate the antioxidant response element transcription system. Mol Cancer Ther 4:177-186
24. Macleod KF, Sherry N, Hannon G, Beach D, Tokino T, Kinzler K, Vogelstein B, Jacks T (1995) p53-dependent and independent expression of p2l during cell growth, differentiation, and DNA damage. Genes Dev 9:935-944
25. Liu Y, Martindale JL, Gorospe M, Holbrook NJ (1996) Regulation of p2lWAF1/CIP1 expression through mitogen-activated protein kinase signaling pathway. Cancer Res 56:31-35
26. LaBaer J, Garrett MD, Stevenson LF, Slingerland JM, Sandhu C, Chou HS, Fattaey A, Harlow E (1997) New functional activities for the p21 family of CDK inhibitors. Genes Dev 11:847-862
27. Zhang H, Hannon GJ, Beach D (1994) p2l -containing cyclin kinases exist in both active and inactive states. Genes Dev 8:1750-1758
28. Cheng M, Olivier P, Diehl JA, Fero M, Roussel MF, Roberts JM, Sherr CJ (1999) The p21(Cip1) and p27(Kip1) CDK 'inhibitors' are essential activators of cyclin D-dependent kinases in murine fibroblasts. Embo J 18:1571-1583
29. Hiyama H, Iavarone A, LaBaer J, Reeves SA (1997) Regulated ectopic expression of cyclin D1 induces transcriptional activation of the cdk inhibitor p21 gene without altering cell cycle progression. Oncogene 14:2533-2542
30. Ben-Dor A, Nahum A, Danilenko M, Giat Y, Stahl W, Martin HD, Emmerich T, Noy N, Levy J, Sharoni Y (2001) Effects of acyclo-retinoic acid and lycopene on activation of the retinoic acid receptor and proliferation of mammary cancer cells. Arch Biochern Biophys 391:295-302
31. Gucev ZS, Oh Y, Kelley KM, Rosenfeld RG (1996) Insulin-like growth factor binding protein 3 mediates retinoic acid- and transforming growth factor beta2-induced growth inhibition in human breast cancer cells. Cancer Res 56:1545-1550
32. Karas M, Danilenko M, Fishman D, LeRoith D, Levy J, Sharoni Y (1997) Membrane-associated insulin-like growth factor-binding protein-3 inhibits insulin-like growth factor-I-induced insulin-like growth factor-I receptor signaling in ishikawa endometrial cancer cells. J Biol Chem 272:16514-16520
33. Boyle JO, Langenfeld J, Lonardo F, Sekula D, Reczek P, Rusch V, Dawson MI, Dmitrovsky E (1999) Cyclin D1 proteolysis: a retinoid chemoprevention signal in normal, immortalized, and transformed human bronchial epithelial cells. J Natl Cancer Inst 91:373-379